Trastuzumab-gyyp
Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.[3][4][5][6] It is specifically used for cancer that is HER2 receptor positive.[3] It may be used by itself or together with other chemotherapy medication.[3] Trastuzumab is given by slow injection into a vein and injection just under the skin.[3][7]
Common side effects include fever, infection, cough, headache, trouble sleeping, and rash.[3] Other severe side effects include heart failure, allergic reactions, and lung disease.[3] Use during pregnancy may harm the baby.[2] Trastuzumab works by binding to the HER2 receptor and slowing down cell duplication.[3]
Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000.[8][6] It is on the World Health Organization’s List of Essential Medicines.[9] A biosimilar was approved in the European Union in November 2017, and in the United States in December 2018.[10][11][12]